Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber Brigham Cancer Center provides comprehensive care and promising new therapies to people with multiple myeloma. We are a highly specialized center focusing exclusively on multiple myeloma diagnostics, treatment planning, therapy, and research.
Our dedicated team of laboratory and clinical-based investigators and physicians have changed the fundamental understanding of the mechanics of this disease, leading to effective new treatments. Their research in genomic sequencing and related treatments is currently setting the standard of care for the disease around the world, and at any given time, we have numerous clinical trials for multiple myeloma underway.
The Center is part of the Hematologic Oncology Treatment Center at Dana-Farber Brigham Cancer Center, which includes the hematopoietic Stem Cell Transplantation Program — one of the largest and most experienced in the world.
Exceptional Care for Patients with Multiple Myeloma Comprehensive evaluation and diagnosis, personalized treatment plans, and options for conventional and innovative treatments. Access to clinical trials involving novel therapies (Phase I/II/III studies). Treatment plans for initial therapy, maintenance, and relapsed disease, as well as expertise in autologous stem cell transplant and CAR T-cell therapy for appropriate patients. Innovative strategies to manage toxicity, including peripheral neuropathy. Center for Prevention of Progression for patients with MGUS and smoldering multiple myeloma, precursor conditions of multiple myeloma Founding institution of the Multiple Myeloma Research Consortium, which brings together researchers and academic institutions around the world. Care plans tailored to the needs of each patient, from the first meeting through subsequent treatments in the years to come. Consultations and second opinions for patients and physicians around the world. Physician-scientists who are not only part of the care team, but who also work in our labs to bring new and more effective treatments to patients quickly. Treatment plans developed by a multidisciplinary team that works closely together to ensure that every approach is considered. We Treat You, Not Just Your Cancer Our entire team is here to support you throughout treatment and during recovery. You and your family have access to our full range of support services.
Our entire team is here to support you throughout treatment and during recovery. You and your family have access to our full range of support services.
New Patient Appointments 877-442-3324
View videos on research advances presented at our Multiple Myeloma Patient Symposium
Clinical Trials Questions?
877-DF-TRIAL (877-338-7425)
As a new Dana-Farber patient, find answers to questions about your first visit: what to bring, how to find us, where to park, and how to prepare.
We offer a wide range of services, from financial planning to creative arts to spiritual counsel, to support our patients through their cancer experiences.
See patient satisfaction survey results for different Dana-Farber locations collected by Press Ganey, an independent company experienced in patient satisfaction surveying.
The Blum Resource Center provides patients and family members with a comfortable environment to learn more about disease treatment and management.
Our nutrition experts help patients follow a healthy diet during and after cancer treatment.
The Leonard P. Zakim Center for Integrative Therapies and Healthy Living is dedicated to enhancing the quality of life for cancer patients and their families by incorporating complementary therapies into traditional cancer care.